Passage Bio Inc. (PASG) PT Raised to $45 at Chardan Capital Markets

March 8, 2021 6:40 AM EST
Get Alerts PASG Hot Sheet
Price: $13.56 -3.14%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 11 | New: 50
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Chardan Capital Markets analyst Gbola Amusa raised the price target on Passage Bio Inc. (NASDAQ: PASG) to $45.00 (from $35.50) while maintaining a Buy rating.

The analyst commented, "Post the recent announced FDA clearance on 3 IND applications for 3 different assets (i.e. PBGM01 on 4 January 2021, PBFT02 on 28 January 2021, and PBKR03 on 8 February 2021), we now update our financial model to increase our probability of success on PBFT02 and PBKR03, each from 25% to 35%, thus driving up our PASG price target by 26.8% from $35.50 to $45."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Chardan Capital Markets, Gbola Amusa, FDA